Related Experiment Videos
Neurologists' attitudes regarding rt-PA for acute ischemic stroke
C Villar-Cordova1, L B Morgenstern, J S Barnholtz
1Department of Neurology, The University of Texas Medical School at Houston, 77030, USA.
Neurology
|May 22, 1998
Summary
Texas neurologists showed high interest in using recombinant tissue plasminogen activator (rt-PA) for stroke treatment soon after its FDA approval. Most neurologists who used rt-PA reported positive experiences and would use it again.
Area of Science:
- Neurology
- Cardiovascular Medicine
Background:
- Stroke treatment landscape before rt-PA availability.
- The introduction of recombinant tissue plasminogen activator (rt-PA) as a potential therapy for acute ischemic stroke.
Purpose of the Study:
- To assess the adoption rate and attitudes of Texas neurologists towards using rt-PA for stroke.
- To understand the initial experiences and future intentions of neurologists regarding rt-PA therapy.
Main Methods:
- A survey was conducted among 238 neurologists in Texas.
- The survey collected data on rt-PA usage, willingness to use, and past experiences.
Main Results:
- 16% of surveyed neurologists had already treated stroke patients with rt-PA.
- 97% of those who used rt-PA would administer it again.
- 60% of neurologists who had not yet used rt-PA expressed willingness to treat suitable candidates.
Conclusions:
- A significant majority of Texas neurologists were either using or planning to use rt-PA shortly after its FDA approval.
- Neurologists with experience using rt-PA for stroke reported positive outcomes and experiences.